At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
AZD1208drug
Likely dose
AZD1208 120mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients With Advanced Solid Malignancies Including Malignant Lymphoma
In Brief
A Phase 1 clinical trial evaluating AZD1208 for Advanced Solid Malignancies and Malignant Lymphoma. Completed, enrolled 43 participants across 3 sites in 2 countries.
Detailed Summary
The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid malignancies including malignant lymphoma
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Malignancies, Malignant Lymphoma
CountriesJapan, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJul 2012
Primary CompletionJul 2014
TodayJul 2026
First PostedMay 1, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.2 years ago
Interventions
AZD1208drug
Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose